Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. The stock rose 5.2%, to $11.15, in after-hours trading on Friday ...

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

A bipartisan group of legislators have introduced a bill at the roundhouse that would allow New Mexicans to take psychedelic ...

Legislation to create a program for the medicinal use of psilocybin was introduced today in the New Mexico Senate. Senate Bill 219, the Medical Psilocybin Act, would allow those in New Mexico to ...

The Cambridge, Mass., biotechnology company on Thursday said it received a notice of allowance from the U.S. Patent and Trademark Office regarding the drug candidate, ED-003, which is intended to ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, an analyst ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.